Second Study Strengthens Regulatory Case

Johnson & Johnson reported that Caplyta met the main objective in its second late-stage study evaluating the drug as a treatment for manic episodes associated with bipolar I disorder. The trial compared a daily 42 mg dose against placebo over three weeks in adults experiencing mania, with or without mixed features.

Patients taking Caplyta recorded a 3.7-point greater reduction in mania scores than those receiving placebo, based on a standard rating scale. The company said improvement was detectable as early as the third day of treatment.

The proportion of patients achieving at least a 50% improvement in mania symptoms also favored the drug. Nearly 44% of participants treated with Caplyta reached that threshold, compared with approximately 24% in the placebo group.

The findings follow a positive result from the drug’s first late-stage study in bipolar mania, giving J&J two successful trials to support its planned application to the US Food and Drug Administration.

Expanding Caplyta’s Treatment Potential

Caplyta is already approved in the United States for bipolar depression, schizophrenia and certain cases of major depressive disorder. Approval for bipolar mania would expand its potential use across additional symptoms associated with bipolar I disorder.

Bipolar disorder affects an estimated 36 million people worldwide. Mania, a defining feature of bipolar I disorder, can involve grandiosity, reduced need for sleep, racing thoughts, distractibility and risk-taking behavior.

The second trial’s results provide additional clinical evidence for expanding the drug’s approved indications. The planned FDA submission will be the next regulatory step, although the timing of a decision was not specified.

Commercial Outlook and Acquisition Strategy

Caplyta is also an important asset in J&J’s effort to strengthen its neuroscience business. The company gained access to the drug through its $14.6 billion acquisition of Intra-Cellular Therapies last year.

Analysts at UBS previously estimated that Caplyta could eventually generate peak annual sales above $5 billion. Their sales forecast was approximately $4.3 billion by 2033, reflecting the drug’s commercial potential across its existing and prospective indications.

An additional approval for bipolar mania could broaden the addressable treatment market, although the commercial contribution will depend on the regulatory outcome and subsequent adoption.

What Investors Should Watch Next

The planned FDA filing is the next major milestone for Caplyta. Investors will be watching the submission process and the regulator’s assessment of the two late-stage trials.

The results strengthen the clinical case for expanding the drug’s use, while its existing approvals and acquisition history make Caplyta a significant part of J&J’s neuroscience strategy. The eventual impact on revenue will depend on whether the company secures approval for bipolar mania and how broadly the treatment is adopted.